Late treatment study
et al., European J. Internal Medicine, doi:10.1016/j.ejim.2020.08.019 (Peer Reviewed)
Use of hydroxych loroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study
Retrospective 3,451 hospitalized patients, 30% reduction in mortality with HC
Q after propensity adjustment, HR 0.70 [0.59 - 0.84].
death, ↓30.0%, p<0.0001
Please send us corrections, updates, or comments.